FrancophonIA/ELRC3.0 huggingface dataset:
English: Patients should be closely monitored for signs of toxicity or lack of efficacy if they have been given oritavancin while on a potentially affected compound (e.g. patients should be monitored for bleeding, if concomitantly receiving oritavancin and warfarin) (see section 4.4).
Croatian: Bolesnike je potrebno pomno pratiti kako bi se uočili znakovi toksičnosti ili nedostatak djelotvornosti ako su dobili oritavancin dok su se liječili spojem na koji je oritavancin možda utjecao (npr. bolesnike je potrebno pratiti kako bi se uočilo krvarenje, ako su istodobno primali oritavancin i varfarin) (vidjeti dio 4.4).
English: Orbactiv is an antibiotic that contains the active substance oritavancin.
Croatian: Orbactiv je antibiotik koji sadrži djelatnu tvar oritavancin.
English: If osteomyelitis is suspected or diagnosed, appropriate alternative antibacterial therapy should be instituted.
Croatian: Ako postoji sumnja na osteomijelitis, ili je on dijagnosticiran, treba uvesti odgovarajuće alternativno antibakterijsko liječenje.
English: A standard battery of in vitro and in vivo tests on the genotoxic potential did not reveal any clinically relevant findings.
Croatian: Standardna skupina in vitro i in vivo testova genotoksičnog potencijala nije pokazala klinički značajne nalaze.
English: Moderate, dose-related increases in liver enzymes (alanine transaminase and aspartate transaminase) were observed in rats and dogs and were shown to be reversible upon cessation of treatment.
Croatian: Umjeren porast vrijednosti jetrenih enzima (alanin-transaminaze i aspartat-transaminaze) povezan s dozom opažen je u štakora i pasa i pokazao se reverzibilnim nakon prekida liječenja.
English: Additionally, in vitro human liver microsome studies indicated that oritavancin is not metabolized.
Croatian: Osim toga, ispitivanja na ljudskim jetrenim mikrosomima in vitro pokazala su da se oritavancin ne metabolizira.
English: Oritavancin has been shown to interfere with certain laboratory coagulation tests (see sections 4.3 and 4.5).
Croatian: Uočeno je da oritavancin interferira s određenim laboratorijskim testovima koagulacije (vidjeti dijelove 4.3 i 4.5).
English: Before using oritavancin it is important to inquire carefully about previous hypersensitivity reactions to glycopeptides (e.g. vancomycin, telavancin).
Croatian: Prije primjene oritavancina, važno je pomno se raspitati o prethodnim reakcijama preosjetljivosti na glikopeptide (npr. vankomicin, telavancin).
English: Osteomyelitis
Croatian: Osteomijelitis
English: Mortality was observed in neonatal rats at slightly lower dosage levels than in adults.
Croatian: Smrtnost u novorođenih štakora opažena je pri nešto nižim dozama u odnosu na odrasle.
English: S-warfarin pharmacokinetics were evaluated following a single dose of warfarin 25 mg given alone, or administered at the start, 24, or 72 hours after a single 1,200mg dose of oritavancin.
Croatian: Farmakokinetika S-varfarina procijenjena je nakon primjene jedne doze samog varfarina od 25 mg, ili primjene na početku, 24 ili 72 sata nakon jedne doze oritavancina od 1200 mg.
English: In mixed infections where Gram negative and/or certain types of anaerobic bacteria are suspected, oritavancin should be coadministered with appropriate antibacterial agent(s).
Croatian: U miješanim infekcijama kada postoji sumnja na gram-negativne i/ili određene vrste anaerobnih bakterija, oritavancin se mora primjenjivati istodobno s odgovarajućim antibakterijskim lijekom(ovima).
English: Orbactiv may cause dizziness, which can influence your ability to drive or operate machines.
Croatian: Orbactiv može prouzročiti omaglicu, što može utjecati na Vašu sposobnost upravljanja vozilima ili rada sa strojevima.
English: Caution should be used when administering oritavancin concomitantly with medicinal products with a narrow therapeutic window that are predominantly metabolised by one of the affected CYP450 enzymes(e.g., warfarin), as co-administration may increase (e.g., for CYP2C9 substrates) or decrease (e.g., for CYP2D6 substrates) concentrations of the narrow therapeutic range medicinal product.
Croatian: Potreban je oprez kod istodobne primjene oritavancina i lijekova s uskim terapijskim prozorom koji se pretežno metaboliziraju jednim od zahvaćenih CYP450 enzima (npr. varfarin), jer istodobna primjena može povećati (npr. kod supstrata CYP2C9) ili smanjiti (npr. kod supstrata CYP2D6) koncentracije lijeka s uskim terapijskim rasponom.
English: • aPTT for up to 120 hours,
Croatian: • aPTV tijekom 120 sati
English: Clinical efficacy has not been established against the following pathogens although in vitro studies suggest that they would be susceptible to oritavancin in the absence of acquired mechanisms of resistance:
Croatian: Nije utvrđena klinička djelotvornost protiv sljedećih patogena iako ispitivanja in vitro upućuju da bi bili osjetljivi na oritavancin u nedostatku stečenih mehanizama rezistencije:
English: Dizziness may occur and this may have an effect on driving and use of machines (see section 4.8).
Croatian: Može se javiti omaglica, koja može utjecati na upravljanje vozilima i rad sa strojevima (vidjeti dio 4.8).
English: Urticaria, rash, pruritis
Croatian: Urtikarija, osip, svrbež
English: The powder must be reconstituted with water for injections and the resulting concentrate must be diluted in a glucose 5% intravenous infusion bag prior to use.
Croatian: Prašak se mora rekonstituirati s vodom za injekcije, a tako dobiven koncentrat mora se razrijediti prije primjene u vrećici 5%-tne glukoze za intravensku infuziju.
English: Oritavancin exhibits linear pharmacokinetics at a dose up to 1,200 mg.
Croatian: Oritavancin pokazuje linearnu farmakokinetiku u dozi do 1200 mg.
English: The most commonly reported adverse reactions (≥5%) were: nausea, hypersensitivity reactions,
Croatian: Najčešće prijavljivane nuspojave (≥5%) bile su: mučnina, reakcije preosjetljivosti, reakcije na mjestu infuzije i glavobolja.
English: It is unknown whether oritavancin/metabolites are excreted in human milk.
Croatian: Nije poznato izlučuju li se oritavancin/metaboliti u majčino mlijeko.
English: • have or are suspected to have a painful collection of pus on your skin (abscess).
Croatian: • ako imate ili postoji sumnja da imate bolnu nakupinu gnoja na koži (apsces).
English: Orbactiv will be given to you by your doctor or nurse, by infusion (drip) into a vein.
Croatian: Kako ćete dobivati Orbactiv Orbactiv će Vam dati liječnik ili medicinska sestra infuzijom (kapanjem) u venu.
English: Orbactiv may interfere with laboratory tests or self-test that measure how well your blood is clotting (INR) and may cause a false reading up to 12 hours after the infusion.
Croatian: Orbactiv može utjecati na laboratorijske pretrage ili testove za samomjerenje kojima se određuje koliko dobro se Vaša krv zgrušava (INR) i može prouzročiti lažne rezultate do 12 sati nakon infuzije.
English: Mannitol Phosphoric acid
Croatian: manitol fosfatna kiselina
English: Orbactiv is used to treat infections of the skin and underlying tissues.
Croatian: Orbactiv se primjenjuje u liječenju infekcija kože i tkiva ispod kože.
English: Orbactiv should be prepared under aseptic techniques in a pharmacy.
Croatian: Orbactiv se treba pripremiti aseptičkom tehnikom u ljekarni.
English: In a population PK analysis, a relationship between height and clearance was identified, where clearance increased with increasing height.
Croatian: U populacijskoj farmakokinetičkoj analizi utvrđen je odnos između visine i klirensa, pri čemu se klirens povećava s povećanjem visine.
English: In the Phase 3 clinical trials, slightly more cases of newly emergent abscesses were reported in the oritavancin-treated arm than in the vancomycin-treated arm (4.6% vs 3.4%, respectively) (see section 4.8).
Croatian: U kliničkim ispitivanjima faze 3, prijavljeno je nešto više slučajeva novih apscesa u skupini liječenoj oritavancinom nego u skupini liječenoj vankomicinom (4,6% naspram 3,4%) (vidjeti dio 4.8).
English: Cellulitis, abscess (limb and subcutaneous)
Croatian: Celulitis, apsces (na ekstremitetu i potkožni)
English: Efficacy has been demonstrated in clinical studies against the following pathogens that were susceptible to oritavancin in vitro.
Croatian: Djelotvornost se dokazala u kliničkim ispitivanjima protiv sljedećih patogena koji su bili osjetljivi na oritavancin in vitro.
English: There is limited experience in clinical studies in patients with bacteraemia, peripheral vascular disease or neutropenia, in immunocompromised patients, in patients aged > 65 years and in infections due to S. pyogenes.
Croatian: perifernom vaskularnom bolesti ili neutropenijom, u imunokompromitiranih bolesnika, u bolesnika u dobi >65 godina i kod infekcija izazvanih bakterijom S. pyogenes.
English: Oritavancin has a minor influence on the ability to drive and use machines.
Croatian: Oritavancin malo utječe na sposobnost upravljanja vozilima i rada sa strojevima.
English: No data are available on cross-reactivity between oritavancin and other glycopeptides, including vancomycin.
Croatian: Nema podataka o križnoj reaktivnosti između oritavancina i drugih glikopeptida, uključujući vankomicin.
English: • Pain or irritation where the injection was given;
Croatian: • Bol ili nadraženost na mjestu primjene injekcije;
English: Uncommon side effects (may affect up to 1 in 100 patients):
Croatian: Manje česte nuspojave (mogu se javiti u manje od 1 na 100 bolesnika):
English: The pharmacokinetics of oritavancin was examined in the single dose Phase 3 ABSSSI studies in patients with normal renal function, CrCL ≥90 mL/min (n=213), mild renal impairment, CrCL 60-89 mL/min (n=59), moderate renal impairment, CrCL 30-59 mL/min (n=22), and severe renal impairment CrCL <30 mL/min (n=3).
Croatian: CrCL ≥90 ml/min (n= 213), blagim oštećenjem funkcije bubrega, CrCL 60-89 ml/min (n= 59), umjerenim oštećenjem funkcije bubrega, CrCL 30-59 ml/min (n= 22) i teškim oštećenjem funkcije bubrega CrCL <30 ml/min (n= 3).
English: There was no evidence of transplacental transfer of oritavancin in pregnant rats.
Croatian: Nije bilo dokaza transplacentarnog prijenosa oritavancina u skotnih štakora.
English: The appearance of the eosinophilic granules did not occur following single dose administration and did not significantly affect innate macrophage function in vitro at intracellular levels anticipated from a single 1,200 mg dose.
Croatian: Do pojave eozinofilnih zrnaca nije došlo nakon primjene jedne doze niti je to značajno utjecalo na prirodnu funkciju makrofaga in vitro na unutarstaničnoj razini što se očekivalo od jedne doze od 1200 mg.
English: The mean terminal elimination plasma half-life of oritavancin is 245 hours (14.9% CV) based on population PK analysis of ABSSSI patients receiving a single 1,200 mg dose.
Croatian: Srednji poluvijek eliminacije oritavancina iz plazme je 245 sati (14,9% CV) na temelju populacijske farmakokinetičke analize bolesnika s akutnom bakterijskom infekcijom kože i kožnih struktura koji primaju jednokratnu dozu od 1200 mg.
English: Oritavancin exhibits reduced in vitro activity against certain Gram-positive organisms of the genera Lactobacillus, Leuconostoc and Pediococcus that are intrinsically resistant to glycopeptides.
Croatian: Oritavancin pokazuje smanjenu aktivnost in vitro protiv određenih gram-pozitivnih organizama rodova Lactobacillus, Leuconostoc i Pediococcus koji su intrinzično rezistentni na glikopeptide.
English: In the event of overdose, supportive measures should be taken.
Croatian: U slučaju predoziranja, treba primijeniti standardne potporne mjere.
English: The pharmacokinetics of oritavancin in patients with severe hepatic impairment (Child-Pugh Class C) has not been evaluated, however based on pharmacokinetic parameters, severe hepatic impairment is not expected to have an impact on oritavancin exposure.
Croatian: Farmakokinetika oritavancina u bolesnika s teškim oštećenjem funkcije jetre (Child-Pugh stadij C) nije procijenjena, međutim, na temelju farmakokinetičkih parametara, ne očekuje se da bi teško oštećenje funkcije jetre utjecalo na izloženost oritavancinu.
English: Animal studies have revealed no evidence of impaired fertility due to oritavancin at the highest concentrations administered, however, there is no data on the effects of oritavancin on human fertility.
Croatian: Plodnost Ispitivanja na životinjama nisu pokazala štetno djelovanje na plodnost kod primjene najviših koncentracija oritavancina, međutim nema podataka o utjecaju oritavancina na ljudsku plodnost.
English: A screening drug-drug interaction study was conducted in healthy volunteers (n=16) evaluating the concomitant administration of a single 1,200 mg dose of oritavancin with probe substrates for several CYP450 enzymes.
Croatian: Provedeno je ispitivanje probira interakcija između lijekova u zdravih dobrovoljaca (n= 16) kojim se procjenjivala istodobna primjena jedne doze od 1200 mg oritavancina s probnim supstratima za nekoliko enzima CYP450.
English: The results showed no effect of oritavancin on Swarfarin AUC and Cmax.
Croatian: Rezultati nisu pokazali učinke oritavancina na AUC i Cmax S-varfarina.
English: Nausea, vomiting, diarrhoea, constipation
Croatian: Mučnina, povraćanje, proljev, konstipacija
English: Hypoglycaemia, hyperuricaemia
Croatian: Hipoglikemija, hiperurikemija
English: Table 1: Coagulation tests affected by oritavancin Assay
Croatian: Tablica 1: Testovi koagulacije koji su zahvaćeni oritavancinom
English: Oritavancin has been shown to artificially prolong prothrombin time (PT) and international normalised ratio (INR) for up to 12 hours, making the monitoring of the anticoagulation effect of warfarin unreliable up to 12 hours after an oritavancin dose.
Croatian: Istodobna primjena varfarina Uočeno je da oritavancin umjetno produljuje protrombinsko vrijeme (PV) i međunarodni normalizirani omjer (INR) do 12 sati, što čini praćenje antikoagulacijskog učinka varfarina nepouzdanim do 12 sati nakon doze oritavancina.
English: In the clinical programme of 3,017 oritavancin-treated subjects; there was no incidence of accidental overdose of oritavancin.
Croatian: U kliničkom programu s 3017 ispitanika liječenih oritavancinom nije bilo incidencije slučajnog predoziranja oritavancinom.
English: PP (Polypropylene) or PVC (Polyvinyl chloride) bags should be used for administration preparation.
Croatian: Tijekom pripreme za primjenu potrebno je koristiti vrećice od polipropilena (PP) ili polivinilklorida (PVC).
English: Bronchospasm, wheezing
Croatian: Bronhospazam, piskanje
English: Substances metabolised by cytochrome P450
Croatian: Tvari metabolizirane citokromom P450
English: Up to 120 hours
Croatian: Do najviše 120 sati
English: No dedicated studies in dialysis patients have been conducted.
Croatian: Nisu provedena zasebna ispitivanja u bolesnika na dijalizi.
English: Resistance to oritavancin was observed in vitro in vancomycin-resistant isolates of Staphylococcus aureus.
Croatian: Rezistencija na oritavancin opažena je in vitro u izolatima bakterije Staphylococcus aureus otpornim na vankomicin.
English: Both the reconstituted solution and the diluted solution for infusion should be clear, colourless to pale yellow solution.
Croatian: Kako rekonstituirana otopina, tako i razrijeđena otopina za infuziju treba biti bistra, bezbojna do blijedožuta otopina.
English: If newly emergent abscesses occur, appropriate measures should be taken.
Croatian: Ako nastupe novi apscesi, potrebno je poduzeti odgovarajuće mjere.
English: In humans, less than 1% to 5% of the dose was recovered as parent drug in faeces and urine respectively after 2 weeks of collection indicating that oritavancin is slowly excreted unchanged.
Croatian: U ljudi, manje od 1% doze nađeno je u obliku ishodišnog lijeka u fecesu, a 5% u mokraći nakon 2 tjedna uzimanja uzoraka, što pokazuje da se oritavancin sporo izlučuje u neizmijenjenom obliku.
English: The diluted solution should be used immediately.
Croatian: Razrijeđenu otopinu potrebno je odmah primijeniti.
English: There are no or limited amount of data from the use of oritavancin in pregnant women.
Croatian: Nema podataka ili su podaci o primjeni oritavancina u trudnica ograničeni.
English: Drug-laboratory test interactions (see sections 4.3 and 4.4)
Croatian: Interakcija lijeka s laboratorijskim pretragama (vidjeti dijelove 4.3 i 4.4)
English: Up to 18 hours
Croatian: Do najviše 18 sati
English: Interference with assay for coagulation tests
Croatian: Interferencija s testovima koagulacije
English: • Higher than normal levels of eosinophils, a type of white blood cell (eosinophilia);
Croatian: • Povišene razine eozinofila (vrsta bijelih krvnih stanica) u odnosu na normalu (eozinofilija);
English: Minimum inhibitory concentration (MIC) breakpoints established by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) are as follows:
Croatian: Europsko povjerenstvo za ispitivanje osjetljivosti na antimikrobne lijekove (European Committee on Antimicrobial Susceptibility Testing, EUCAST) utvrdilo je sljedeće granične vrijednosti minimalne inhibicijske koncentracije (MIK):
English: • Inflammation surrounding a tendon (known as tenosynovitis);
Croatian: • Upala oko tetive (poznata pod nazivom tenosinovitis);
English: In the two major trials in ABSSSI the types of infections treated were confined to cellulitis, abscesses and wound infections only.
Croatian: U dvama glavnim ispitivanjima akutnih bakterijskih infekcija kože i kožnih struktura, vrste liječenih infekcija bile su ograničene samo na celulitis, apscese i infekcije rana.
English: Population pharmacokinetic analysis indicated that renal impairment had no clinically relevant effect on the exposure of oritavancin.
Croatian: Populacijska farmakokinetička analiza pokazala je da oštećenje funkcije bubrega nema klinički značajnog utjecaja na izloženost oritavancinu.
English: If not used immediately storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 12 hours at 25°C and 24 hours at 2-8°C following dilution in a glucose 5% intravenous infusion bag, unless reconstitution and dilution has taken place in controlled and validated aseptic conditions.
Croatian: Ako se ne primijeni odmah, vrijeme i uvjeti čuvanja prije primjene odgovornost su korisnika i obično ne bi trebali iznositi dulje od 12 sati na temperaturi od 25°C i 24 sata na temperaturi od 2-8°C nakon razrjeđivanja u vrećici 5%-tne glukoze za intravensku infuziju, osim ako se rekonstitucija i razrjeđivanje nisu proveli u kontroliranim i validiranim aseptičkim uvjetima.
English: Parenteral medicinal products should be inspected visually for particulate matter after reconstitution.
Croatian: Lijekove za parenteralnu primjenu treba vizualno pregledati da ne sadrže čestice nakon rekonstitucije.
English: No metabolites were observed in plasma or bile from oritavancin treated dogs and rats, respectively.
Croatian: Nisu opaženi metaboliti u plazmi pasa ni u žuči štakora liječenih oritavancinom.
English: If not used immediately storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 12 hours at 25°C and 24 hours at 2-8°C for Orbactiv diluted in glucose 5% intravenous infusion bag, unless reconstitution and dilution has taken place in controlled and validated aseptic conditions.
Croatian: Ako se ne primijeni odmah, vrijeme i uvjeti čuvanja prije primjene odgovornost su korisnika i obično ne bi trebali iznositi dulje od 12 sati na temperaturi od 25°C i 24 sata na temperaturi od 2-8°C za Orbactiv razrijeđen u vrećici 5%-tne glukoze za intravensku infuziju, osim ako se rekonstitucija i razrjeđivanje nisu proveli u kontroliranim i validiranim aseptičkim uvjetima.
English: Oritavancin binds to and prevents the action of the phospholipid reagents which activate coagulation in commonly used laboratory coagulation tests.
Croatian: Oritavancin se veže za i sprječava djelovanje fosfolipidnih reagensa koji aktiviraju zgrušavanje u uobičajenim laboratorijskim testovima koagulacije.
English: Population PK analysis from the single dose Phase 3 ABSSSI studies in patients indicated that gender, age, weight, or race had no clinically relevant effect on the exposure of oritavancin.
Croatian: Populacijska FK analiza ispitivanja akutnih bakterijskih infekcija kože i kožnih struktura faze 3 s jednom dozom u bolesnika pokazala je da spol, dob, tjelesna težina ili rasa nisu imali klinički značajan utjecaj na izloženost oritavancinu.
English: The reconstituted solution should be further diluted in glucose 50 mg/ml (5%) intravenous infusion bag immediately.
Croatian: Rekonstituiranu otopinu potrebno je odmah dodatno razrijediti u vrećici glukoze od 50 mg/ml (5%) za intravensku infuziju.
English: Three Orbactiv 400 mg vials need to be reconstituted and diluted to prepare a single once-only 1,200 mg IV dose.
Croatian: Potrebno je rekonstituirati i razrijediti tri bočice lijeka Orbactiv od 400 mg za pripremu jedne jednokratne intravenske doze od 1200 mg.
English: • Withdraw 40 mL from each of the three reconstituted vials and add to D5W intravenous bag to bring the bag volume to 1,000 mL.
Croatian: • Izvucite 40 ml iz svake od tri rekonstituirane bočice i dodajte u vrećicu 5%-tne vodene otopine glukoze za intravensku primjenu kako bi volumen u vrećici bio 1000 ml.
English: Clostridioides difficile-associated diarrhoea
Croatian: Proljev povezan s Clostridioides difficile
English: 1,200 mg administered as a single dose by intravenous infusion over 3 hours.
Croatian: Jedna doza od 1200 mg primijenjena intravenskom infuzijom u trajanju od 3 sata.
English: Your doctor will monitor you in case this happens and treat you if necessary.
Croatian: Vaš će Vas liječnik pomno pratiti ako se to dogodi i liječiti po potrebi.
English: There is no known cross-resistance between oritavancin and non-glycopeptide classes of antibiotics.
Croatian: Nema poznate križne rezistencije između oritavancina i neglikopeptidnih skupina antibiotika.
English: Therefore, it is important to consider this diagnosis in patients who present with diarrhoea subsequent to the administration of oritavancin (see section 4.8).
Croatian: Stoga je ovu dijagnozu nužno uzeti u obzir u bolesnika koji se javljaju zbog proljeva neposredno nakon primjene oritavancina (vidjeti dio 4.8).
English: • Activated Clotting Time (ACT) for up to 24 hours,
Croatian: • aktivirano vrijeme zgrušavanja (AVZ) tijekom 24 sata
English: Oritavancin was found to be a nonspecific, weak inhibitor (CYP2C9 and CYP2C19) or a weak inducer (CYP3A4 and CYP2D6) of several CYP isoforms.
Croatian: CYP2C19) ili slabim induktorom (CYP3A4 i CYP2D6) nekoliko CYP izoformi.
English: • Each vial should be swirled gently to avoid foaming and ensure that all Orbactiv powder is completely reconstituted in solution.
Croatian: • Svaku bočicu treba nježno okretati kako bi se spriječilo stvaranje pjene i osiguralo da se sav prašak lijeka Orbactiv potpuno rekonstituira u otopini.
English: Intravenous infusions of oritavancin can cause reactions that resemble “red man syndrome”, including flushing of the upper body, urticaria, pruritis and/or rash.
Croatian: Intravenske infuzije oritavancina mogu prouzročiti reakcije nalik „sindromu crvenog čovjeka“, uključujući nalete crvenila u gornjem dijelu tijela, urtikariju, svrbež i/ili osip.
English: For patients who require aPTT monitoring within 120 hours of oritavancin dosing, a non-phospholipid dependent coagulation test such as a Factor Xa (chromogenic) assay or an alternative anticoagulant not requiring aPTT monitoring may be considered.
Croatian: Kod bolesnika kojima je potrebno praćenje aPTV-a unutar 120 sati nakon doze oritavancina može se razmotriti uporaba testa koagulacije neovisnog o fosfolipidima, npr. (kromogeni) test faktora Xa ili primjena drugog antikoagulansa koji ne zahtijeva praćenje aPTV-a.
English: Tenosynovitis
Croatian: Tenosinovitis
English: Your doctor will treat you as necessary.
Croatian: Vaš će Vas liječnik liječiti ako je potrebno.
English: Intravenous infusions of Orbactiv can cause flushing of the upper body, hives, itching and/or rashes.
Croatian: Intravenske infuzije lijeka Orbactiv mogu izazvati nalete crvenila u gornjem dijelu tijela, koprivnjaču, svrbež i/ili osip.